
RNTX Stock Forecast & Price Target
RNTX Analyst Ratings
Bulls say
Rein Therapeutics Inc is positioned favorably due to its focus on developing therapies for orphan pulmonary and fibrosis indications, highlighted by its promising Phase 2-ready clinical assets. The company’s clinical trials, particularly for LTI-03 and LTI-01, have demonstrated positive safety and biomarker activity results, which support the potential effectiveness of its treatments in markets with limited competition and inadequate existing therapies. Additionally, a favorable risk-reward opportunity exists for investors, contingent on the company's ability to extend its cash runway, enhancing the appeal of its innovative pipeline set to address substantial unmet medical needs.
Bears say
Rein Therapeutics Inc has experienced a significant decline in its stock value, falling 50% year-to-date in 2025, compared to a mere 3.5% drop in the XBI index, primarily due to a halt in patient enrollment for trials in the U.S. This pause in enrollment has generated considerable uncertainty regarding the company's clinical progression and potential market trajectory. Additionally, concerning data has emerged, indicating that lower sRAGE levels are associated with poor survival outcomes in patients with Idiopathic Pulmonary Fibrosis, which may negatively impact the perceived efficacy and development viability of the company's lead product candidate, LTI-03.
This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNTX Analyst Forecast & Price Prediction
Start investing in RNTX
Order type
Buy in
Order amount
Est. shares
0 shares